A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis

Clinical trial NCT04967508 · COMPLETED

Trial details

NCT number: NCT04967508
Sponsor: Samsung Bioepis Co., Ltd.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Psoriasis Moderate to Severe Plaque Psoriasis

Start date: 2021-07-06
Primary completion: 2022-02-24
Enrollment: 503

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.